Trevena, Inc. (TRVN)
TRVN Stock Price Chart
Explore Trevena, Inc. interactive price chart. Choose custom timeframes to analyze TRVN price movements and trends.
TRVN Company Profile
Discover essential business fundamentals and corporate details for Trevena, Inc. (TRVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2014
Employees
23.00
Website
https://www.trevena.comCEO
Carrie L. Bourdow
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
TRVN Financial Timeline
Browse a chronological timeline of Trevena, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Nov 2025
Earnings released on 4 Jun 2025
Earnings released on 29 May 2025
Earnings released on 6 May 2025
Earnings released on 7 Nov 2024
EPS came in at -$5.79 surpassing the estimated -$7.32 by +20.90%, while revenue for the quarter reached $283.00K .
Stock split effective on 13 Aug 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2024
EPS came in at -$5.75 surpassing the estimated -$9.25 by +37.84%, while revenue for the quarter reached $325.00K .
Earnings released on 1 Apr 2024
EPS came in at -$26.50 falling short of the estimated -$13.00 by -103.85%, while revenue for the quarter reached $20.00K , missing expectations by -86.06%.
Earnings released on 28 Mar 2024
EPS came in at -$1.06 falling short of the estimated -$0.38 by -178.95%, while revenue for the quarter reached -$81.00K .
Earnings released on 14 Nov 2023
EPS came in at -$14.25 falling short of the estimated -$0.15 by -9.40K%, while revenue for the quarter reached $180.00K , beating expectations by +80.00%.
Earnings released on 14 Aug 2023
EPS came in at -$17.25 falling short of the estimated -$11.25 by -53.33%, while revenue for the quarter reached $3.02M , beating expectations by +655.25%.
Earnings released on 15 May 2023
EPS came in at -$20.25 surpassing the estimated -$21.25 by +4.71%, while revenue for the quarter reached $6.00K , missing expectations by -97.39%.
Earnings released on 30 Mar 2023
EPS came in at -$18.25 falling short of the estimated $1.75 by -1.14K%, while revenue for the quarter reached $300.00K , meeting expectations.
Stock split effective on 10 Nov 2022
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2022
EPS came in at -$56.25 matching the estimated -$56.25, while revenue for the quarter reached -$438.00K , missing expectations by -200.29%.
Earnings released on 11 Aug 2022
EPS came in at -$56.25 surpassing the estimated -$68.75 by +18.18%.
Earnings released on 11 May 2022
EPS came in at -$62.50 falling short of the estimated -$56.25 by -11.11%, while revenue for the quarter reached $20.00K , missing expectations by -96.46%.
Earnings released on 31 Mar 2022
EPS came in at -$50.00 surpassing the estimated -$56.25 by +11.11%, while revenue for the quarter reached -$1.00K , missing expectations by -100.22%.
Earnings released on 15 Nov 2021
EPS came in at -$50.00 surpassing the estimated -$56.25 by +11.11%, while revenue for the quarter reached $181.00K , missing expectations by -74.51%.
Earnings released on 12 Aug 2021
EPS came in at -$56.25 falling short of the estimated -$50.00 by -12.50%, while revenue for the quarter reached $178.00K , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$37.50 surpassing the estimated -$50.00 by +25.00%, while revenue for the quarter reached $209.00K , missing expectations by -81.83%.
Earnings released on 9 Mar 2021
EPS came in at -$50.00 falling short of the estimated -$1.50 by -3.23K%, while revenue for the quarter reached $69.00K , missing expectations by -68.64%.
Earnings released on 2 Nov 2020
EPS came in at -$25.00 matching the estimated -$25.00, while revenue for the quarter reached $3.00M , meeting expectations.
TRVN Stock Performance
Access detailed TRVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.